Table 2. Clinicopathological features by GOT1 status in the screening cohort.
| Characteristic | Screening cohort N = 175 |
GOT1+ N = 89 |
GOT1− N = 86 |
P high vs. low |
|---|---|---|---|---|
| Sex, n (%) | ||||
| Male | 103 (59%) | 46 (52%) | 57 (66%) | 0.07 |
| Female | 72 (41%) | 43 (48%) | 29 (34%) | |
| Age – yr | ||||
| Median | 66.1 | 66 | 67 | 0.26 |
| range | 34–87 | 34–87 | 40–82 | |
| ≥ 65 y | 96 | 49 (55%) | 47 (55%) | 1.00 |
| Site, n (%) | ||||
| Head | 148 (85%) | 79 (89%) | 69 (81%) | 0.20 |
| Body + Tail | 26 (15%) | 10 (11%) | 16 (19%) | |
| Tumor Size, n (%) | ||||
| T1/2 | 21 (12%) | 14 (16%) | 7 (8%) | 0.16 |
| T3/4 | 154 (88%) | 75 (84%) | 79 (92%) | |
| Nodal Metastasis, n (%) | ||||
| N0 | 47 (27%) | 24 (27%) | 23 (27%) | 1.0 |
| N1 | 127 (73%) | 65 (73%) | 62 (73%) | |
| Systemic Metastasis, n (%) | ||||
| M0 | 162 (93%) | 83 (93%) | 79 (92%) | 0.78 |
| M1 | 13 (7%) | 6 (7%) | 7 (8%) | |
| Stage Grouping, n (%) | ||||
| I/II | 156 (89%) | 80 (90%) | 76 (88%) | 0.38 |
| III/IV | 19 (11%) | 9 (10%) | 10 (12%) | |
| Histological Grade, n (%) | ||||
| G1/2 | 116 (66%) | 65 (73%) | 51 (60%) | 0.08 |
| G3/4 | 59 (34%) | 24 (27%) | 34 (40%) |
P-values from t-test or Fisher's exact test.